The Role of Long Noncoding RNA AL161431.1 in the Development and Progression of Pancreatic Cancer

Pancreatic cancer is known for its notorious fast progression and poor prognosis. Long noncoding RNA (lncRNA) AL161431.1 has been reported to be involved in the pathogenesis of different cancers. In this study, we explored the role of lncRNA AL161431.1 in the development and progression of pancreati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in oncology Ročník 11; s. 666313
Hlavní autoři: Ma, Gang, Li, Guichen, Fan, Wufeng, Xu, Yuanhong, Song, Shaowei, Guo, Kejian, Liu, Zhe
Médium: Journal Article
Jazyk:angličtina
Vydáno: Frontiers Media S.A 30.07.2021
Témata:
bioinformatics
diagnosis
epithelial mesenchymal transition (EMT)
long noncoding RNA
Oncology
pancreatic cancer
ISSN:2234-943X, 2234-943X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Pancreatic cancer is known for its notorious fast progression and poor prognosis. Long noncoding RNA (lncRNA) AL161431.1 has been reported to be involved in the pathogenesis of different cancers. In this study, we explored the role of lncRNA AL161431.1 in the development and progression of pancreatic cancer by bioinformatic analysis, in vitro and in vivo experiments in pancreatic cancer BxPC-3 and SW1990 cells, as well as clinical samples. We found that lncRNA AL161431.1 was highly expressed in pancreatic cancer cells and tissues. Knock down of lncRNA AL161431.1 led to increased cancer cell death and cell cycle arrest. Xenograft growth of SW1990 cells with stable knockdown of lncRNA AL161431.1 in mice was significantly slower than that of SW1990 cells with scrambled control shRNA. Finally, we showed the involvement of lncRNA AL161431.1 in pancreatic cancer was related to its promotion of epithelial mesenchymal transition process.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Edited by: Pascale Cohen, Université Claude Bernard Lyon 1, France
Reviewed by: Zhongjie Shi, Wayne State University, United States; Dong Pan, Duke University, United States
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.666313